Drug Discovery in Cancer Epigenetics (Translational Epigenetics Series)
Original price was: $200.18.$117.75Current price is: $117.75.
9780128022085, Academic Press, Egger, Gerda
Author: Egger, Gerda
Brand: Academic Press
Edition: 1
ISBN: 9780128022085
Release Date: 30-12-2015
Package Dimensions: 9.1 x 6.6 x 1.1 inches
Languages: English
Binding: hardcover
Number Of Pages: 498
Details: Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic. Highlights the potential of epigenetic alterations in cancer for drug development Covers the tools and methods for epigenetic drug discovery, preclinical and clinical testing, and clinical implications of epigenetic therapy Provides important information regarding putative epigenetic targets, epigenetic technologies, networks and consortia for epigenetic drug discovery and routes for translation
User Reviews
Be the first to review “Drug Discovery in Cancer Epigenetics (Translational Epigenetics Series)”
Vendor Information
- Store Name: Adobooks Marketplace
- Vendor: Adobooks Marketplace
- No ratings found yet!
Product Enquiry
Original price was: $200.18.$117.75Current price is: $117.75.


There are no reviews yet.